Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of DFL24498 eye drops in adults with atopic keratoconjunctivitis
2025-522291-83-00Phase 3Authorised
- Sponsor
- Dompé
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of isocyclosporin A in atopic keratoconjunctivitis (AKC) (2 arms), sponsored by Dompé. Primary endpoint: Change from baseline at week 6 in ocular itching score. Planned start Nov 2025; status: authorised.
02
Drugs
isocyclosporin A
03
Conditions
atopic keratoconjunctivitis (AKC)
Beyond the preview
Go deeper on 2025-522291-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522291-83-00.